A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells

Bioconjugate Chemistry

Volumn 18, Issue 6, 2007, Pages 2122-2130

  Vaidyanathan, Ganesan ^a   Affleck, Donna J ^a   Norman, Joseph ^a   O'Dorisio, Susan ^b   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; TUMORS;

CELL LINES; CELL-BE; CELL/B.E; CELL/BE; ENHANCED UPTAKE; HUMAN NEUROBLASTOMA; NEUROBLASTOMA CELLS; OCTREOTIDE; SOMATOSTATIN RECEPTORS; TIME POINTS;

CELL CULTURE;

(3 IODOBENZYL)GUANIDINE I 125; DESIPRAMINE; N (4 GUANIDINOMETHYL 2 IODOBENZOYL)OCTREOTATE[1 DEXTRO PHENYLALANINE I 131]; N (4 GUANIDINOMETHYL 3 IODOBENZOYL)OCTREOTATE[1 DEXTRO PHENYLALANINE I 125]; N ALPHA (1 DEOXY DEXTRO FRUCTOSYL)IODOOCTREOTATE[3 TYROSINE I 125]; NORADRENALIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; TIN; UNCLASSIFIED DRUG;

ARTICLE; CLONE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG CONJUGATION; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; ISOMER; NEUROBLASTOMA CELL; PRECURSOR; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; RADIOIODINATION;

EID: 36849057734     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700240r     Document Type: Article

References (54)

1. Jaques, S., Jr., Tobes, M. C., and Sisson, J. C. (1987) Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 47, 3920-8.
2. Smets, L. A., Loesberg, C., Janssen, M., Metwally, E. A., and Huiskamp, R. (1989) Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 49, 2941-4.
3. Matthay, K. K., Tan, J. C., Villabianca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., Seeger, R. C., and Maris, J. M. (2006) Phase I dose escalation of iodine-131- metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 24, 500-6.
4. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett. 228, 221-7.
5. Albers, A. R., O'Dorisio, M. S., Balster, D. A., Caprara, M., Gosh, P., Chen, F., Hoeger, C., Rivier, J., Wenger, G. D., O'Dorisio, T. M., and Qualman, S. J. (2000) Somatostatin receptor gene expression in neuroblastoma. Regul. Pept. 88, 61-73.
6. Orlando, C., Raggi, C. C., Bagnoni, L., Sestini, R., Briganti, V., La Cava, G., Bernini, G., Tonini, G. P., Pazzagli, M., Serio, M., and Maggi, M. (2001) Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium - 111-pentetreotide. Med. Pediatr. Oncol. 36, 224-6.
7. Smitha, M. C., Maggi, M., and Orlando, C. (2004) Somatostatin receptors in non-endocrine tumours. Dig. Liver Dis. 36, S78-85 (Suppl. 1).
8. Pashankar, F. D., O'Dorisio, M. S., and Menda, Y. (2005) MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J. Nucl. Med. 46, 55S-61S (Suppl. 1).
9. 90Y-labeled somatostatin analogs. J. Nucl. Med. 46, 13S-7S (Suppl. 1).
10. Kwekkeboom, D. J., Mueller-Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S., Kvols, L. K., O'Dorisio, T, M., Valkema, R., Bodei, L., Chinol, M., Maecke, H. R., and Krenning, E. P. (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 46, 62S-6S (Suppl. 1).
11. 3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med. 36, 147-56.
12. Kaltsas, G. A., Mukherjee, J. J., and Grossman, A. B. (2001) The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann. Oncol, 12, S47-50 (Suppl. 2).
13. 111In-pentetreotide in carcinoid tumours. Eur. J. Cancer 32A, 1924-32.
14. 111In]octreotide uptake in benign and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86, 685-93.
15. 123I-MIBG scintigraphy in the diagnosis of small intestinal carcinoid tumors-results of a comparative investigation. Nuklearmedizin 35, 53-8.
16. 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma. Int. J. Cancer 57, 245-6.
17. Tenenbaum, F., Lumbroso, J., Schlumberger, M., Mure, A., Plouin, P. F., Caillou, B., and Parmentier, C. (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J. Nucl. Med. 36, 1-6.
18. Wiseman, G. A., and Kvols, L. K. (1995) Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. Nucl. Med. 25, 272-8.
19. Ezziddin, S., Logvinski, T., Yong-Hing, C., Ahmadzadehfar, H., Fischer, H. P., Palmedo, H., Bucerius, J., Reinhardt, M. J., and Biersack, H. J. (2006) Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 47, 223-33.
20. Bombardiert, E., Maccauro, M., De Deckere, E., Savelli, G., and Chiti, A. (2001) Nuclear medicine imaging of neuroendocrine tumours. Ann. Oncol. 12, S51-61 (Suppl. 2).
21. Kaltsas, G., Rockall, A., Papadogias, D., Reznek, R., and Grossman, A. B. (2004) Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 151, 15-27.
22. 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J. Nucl. Med. 47, 660-7.
23. Geuze, H. J., Slot, J. W., Strous, G. J., Peppard, J., von Figura, K., Hasilik, A., and Schwartz, A. L. (1984) Intracellular receptor sorting during endocytosis: comparative immunoelectron microscopy of multiple receptors in rat liver. Cell 37, 195-204.
24. Mier, W., Eritja, R., Mohammed, A., Haberkorn, U., and Eisenhut, M. (2000) Preparation and evaluation of tumor-targeting peptide-oligonucleotide conjugates. Bioconjugate Chem. 11, 855-60.
25. Sun, L., Fuselier, J. A., Murphy, W. A., and Coy, D. H. (2002) Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides 23, 1557-65.
26. Kiaris, H., Schally, A. V., Nagy, A., Szepeshazi, K., Hebert, F., and Halmos, G. (2001) A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur. J. Cancer 37, 620-8.
27. Huang, C. M., Wu, Y. T., and Chen, S. T. (2000) Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 7, 453-61.
28. Capello, A., Krenning, E. P., Bernard, B. F., Breeman, W. A., Erion, J. L., and de Jong, M. (2006) Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med. 47, 122-9.
29. DeNardo, S. J. (2006) Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging. J. Nucl. Med. 47, 4-5.
30. Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., and Kiessling, L. L. (2007) Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2, 119-27.
31. Mammen, M., Choi, S.-K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 37, 2754-2794.
32. Morphy, R., and Rankovic, Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48, 6523-43.
33. Reubi, J. C., and Waser, B. (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781-93.
34. Vagner, J., Handl, H. L., Gillies, R. J., and Hruby, V. J. (2004) Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg. Med. Chem. Lett. 14, 211-5.
35. Qiu, Q., Domarkas, J., Banerjee, R., Merayo, N., Brahimi, F., McNamee, J. P., Gibbs, B. F., and Jean-Claude, B. J. (2007) The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin. Cancer Res. 13, 331-40.
36. 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides 25, 2087-97.
37. 131I]iodobenzylguanidine. Appl. Radiat. Isot. 44, 621-8.
38. Biedler, J. L., Roffler-Tarlov, S., Schachner, M., and Freedman, L. S. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38, 3751-7.
39. Biedler, J. L., Helson, L., and Spengler, B. A. (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33, 2643-52.
40. Stirnweis, J., Boehmer, F. D., and Liebmann, C. (2002) The putative somatostatin antagonist, cyclo-(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[BZL]), may act as potent antiproliferative agonist. Peptides 23, 1503-6.
41. Cattaneo, M. G., Taylor, J. E., Culler, M. D., Nisoli, E., and Vicentini, L. M. (2000) Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett. 481, 271-6.
42. Connor, M., Yeo, A., and Henderson, G. (1997) Neuropeptide Y Y2 receptor and somatostatin sst2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br. J. Pharmacol. 120, 455-63.
43. Kaltenbach, J. P., Kaltenbach, M. H., and Lyons, W. B. (1958) Nigrosin as a dye for differentiating live and dead ascites cells. Exp. Cell Res. 15, 112-7.
44. Panetta, C. A., Garlick, S. M., Durst, H. D., Longo, F. R., and Ward, J. R. (1990) Synthesis of 4-alkyl-2-iodosobenzoic acids - potent catalysts for the hydrolysis of phosphorus esters. J. Org. Chem. 55, 5202-5205.
45. Vaidyanathan, G., Shankar, S., Affleck, D. J., Welsh, P. C., Slade, S. K., and Zalutsky, M. R. (2001) Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. Bioconjugate Chem. 12, 798-806.
46. 123I] iomazenil by iododestannylation: implications for the reaction mechanism. Appl. Radiat. Isot. 45, 63-8.
47. Smets, L. A., Janssen, M., Metwally, E., and Loesberg, C. (1990) Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem. Pharmacol. 39, 1959-64.
48. Vaidyanathan, G., Welsh, P. C., Vitorello, K. C., Snyder, S., Friedman, H. S., and Zalutsky, M. R. (2004) A 4-methyl-substituted meta- iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Eur. J. Nucl. Med. Mol. Imaging 31, 1362-70.
49. Vaidyanathan, G., Affleck, D. J., and Zalutsky, M. R. (2005) No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. Appl. Radiat. Isot. 62, 435-40.
50. Iavarone, A., Lasorella, A., Servidei, T., Riccardi, R., and Mastrangelo, R. (1993) Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res. 53, 304-9.
51. Vaidyanathan, G., Friedman, H. S., Affleck, D. J., Schottelius, M., Wester, H. J., and Zalutsky, M. R. (2003) Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin. Cancer Res. 9, 1868-76.
52. 3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J. Med. Chem. 48, 2778-89.
53. Wieland, D. M., Mangner, T. J., Inbasekaran, M. N., Brown, L. E., and Wu, J. L. (1984) Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J. Med. Chem. 27, 149-55.
54. 131I]iodobenzylguanidine. J. Nucl. Med. 21, 349-53.